183 related articles for article (PubMed ID: 36016696)
1. A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer.
Avanzino BC; Prabhakar K; Dalvi P; Hartstein S; Kehm H; Balasubramani A; Boudreau AA; Buelow B; Chang K; Davison LM; Iyer S; Kalwit V; Lewis Wilson K; Malik-Chaudhry HK; Pierson W; Pineda G; Rangaswamy US; Saiganesh S; Schellenberger U; Ugamraj HS; Yabut RD; Buelow R; Chapman J; Trinklein ND; Harris KE
Oncoimmunology; 2022; 11(1):2113697. PubMed ID: 36016696
[TBL] [Abstract][Full Text] [Related]
2. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.
Dang K; Castello G; Clarke SC; Li Y; Balasubramani A; Boudreau A; Davison L; Harris KE; Pham D; Sankaran P; Ugamraj HS; Deng R; Kwek S; Starzinski A; Iyer S; van Schooten W; Schellenberger U; Sun W; Trinklein ND; Buelow R; Buelow B; Fong L; Dalvi P
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088740
[TBL] [Abstract][Full Text] [Related]
3. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL.
Malik-Chaudhry HK; Prabhakar K; Ugamraj HS; Boudreau AA; Buelow B; Dang K; Davison LM; Harris KE; Jorgensen B; Ogana H; Pham D; Schellenberger U; Van Schooten W; Buelow R; Iyer S; Trinklein ND; Rangaswamy US
MAbs; 2021; 13(1):1890411. PubMed ID: 33818299
[TBL] [Abstract][Full Text] [Related]
4. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
[TBL] [Abstract][Full Text] [Related]
5. Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-
Hou Z; Gattoc L; O'Connor C; Yang S; Wallace-Povirk A; George C; Orr S; Polin L; White K; Kushner J; Morris RT; Gangjee A; Matherly LH
Mol Cancer Ther; 2017 May; 16(5):819-830. PubMed ID: 28138029
[TBL] [Abstract][Full Text] [Related]
6. Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter.
Saito S; Koya Y; Kajiyama H; Yamashita M; Kikkawa F; Nawa A
Cancer Sci; 2020 May; 111(5):1794-1804. PubMed ID: 32154964
[TBL] [Abstract][Full Text] [Related]
7. Development of T-cell engagers selective for cells co-expressing two antigens.
Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
Wen Y; Graybill WS; Previs RA; Hu W; Ivan C; Mangala LS; Zand B; Nick AM; Jennings NB; Dalton HJ; Sehgal V; Ram P; Lee JS; Vivas-Mejia PE; Coleman RL; Sood AK
Clin Cancer Res; 2015 Jan; 21(2):448-59. PubMed ID: 25416196
[TBL] [Abstract][Full Text] [Related]
9. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity.
Rudman SM; Josephs DH; Cambrook H; Karagiannis P; Gilbert AE; Dodev T; Hunt J; Koers A; Montes A; Taams L; Canevari S; Figini M; Blower PJ; Beavil AJ; Nicodemus CF; Corrigan C; Kaye SB; Nestle FO; Gould HJ; Spicer JF; Karagiannis SN
Clin Exp Allergy; 2011 Oct; 41(10):1400-13. PubMed ID: 21569129
[TBL] [Abstract][Full Text] [Related]
10. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
Schutsky K; Song DG; Lynn R; Smith JB; Poussin M; Figini M; Zhao Y; Powell DJ
Oncotarget; 2015 Oct; 6(30):28911-28. PubMed ID: 26359629
[TBL] [Abstract][Full Text] [Related]
11. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
Martin LP; Konner JA; Moore KN; Seward SM; Matulonis UA; Perez RP; Su Y; Berkenblit A; Ruiz-Soto R; Birrer MJ
Gynecol Oncol; 2017 Nov; 147(2):402-407. PubMed ID: 28843653
[TBL] [Abstract][Full Text] [Related]
12. BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control.
McGray AJR; Chiello JL; Tsuji T; Long M; Maraszek K; Gaulin N; Rosario SR; Hess SM; Abrams SI; Kozbor D; Odunsi K; Zsiros E
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37647218
[TBL] [Abstract][Full Text] [Related]
13. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
[TBL] [Abstract][Full Text] [Related]
14. Exploiting the folate receptor α in oncology.
Scaranti M; Cojocaru E; Banerjee S; Banerji U
Nat Rev Clin Oncol; 2020 Jun; 17(6):349-359. PubMed ID: 32152484
[TBL] [Abstract][Full Text] [Related]
15. Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy.
Azaïs H; Queniat G; Bonner C; Kerdraon O; Tardivel M; Jetpisbayeva G; Frochot C; Betrouni N; Collinet P; Mordon S
Int J Gynecol Cancer; 2015 Sep; 25(7):1194-200. PubMed ID: 26244757
[TBL] [Abstract][Full Text] [Related]
16. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).
Song DG; Ye Q; Carpenito C; Poussin M; Wang LP; Ji C; Figini M; June CH; Coukos G; Powell DJ
Cancer Res; 2011 Jul; 71(13):4617-27. PubMed ID: 21546571
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome.
Siu MK; Kong DS; Chan HY; Wong ES; Ip PP; Jiang L; Ngan HY; Le XF; Cheung AN
PLoS One; 2012; 7(11):e47201. PubMed ID: 23144806
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccination against the ovarian carcinoma-associated antigen folate receptor alpha (FRalpha) induces cytotoxic T lymphocyte and antibody responses in mice.
Neglia F; Orengo AM; Cilli M; Meazza R; Tomassetti A; Canevari S; Melani C; Colombo MP; Ferrini S
Cancer Gene Ther; 1999; 6(4):349-57. PubMed ID: 10419053
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study.
Azaïs H; Schmitt C; Tardivel M; Kerdraon O; Stallivieri A; Frochot C; Betrouni N; Collinet P; Mordon S
Photodiagnosis Photodyn Ther; 2016 Mar; 13():130-138. PubMed ID: 26200606
[TBL] [Abstract][Full Text] [Related]
20. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]